About UsJacqueline Meryl Evans, M.D., Ph.D. 
Clinical/Research Interests
Title:
Specialty:
Center/Program Affiliation:
Address:
2315 Stockton Blvd.
Sacramento, CA 95617
Education:
Worcester, Massachusetts
M.D. 1993
City University of New York
New York, New York
Ph.D. 1990
University of Rochester
Rochester, New York
B.A./B.S. 1984
Internships:
Pittsburgh, Pennsylvania
1994
Residency:
Pittsburgh, Pennsylvania
1996
Pediatrics
Fellowships:
Seattle, Washington
2004
Pediatric Critical Care Medicine
Board Certifications:
American Board of Pediatrics, Critical Care Medicine, 2006
Professional Memberships:
California Thoracic Society
Massachusetts Medical Society
Society for Critical Care Medicine
Honors and Awards:
Sigma Xi, Mt. Sinai School of Medicine Chapter, 1988
Select Recent Publications:
Doki T, Mello M, Mock D, Evans JM and Kearns-Jonker, M., Intragraft gene expression profile associated with the induction of tolerance, BMC Immunol. 2008 Feb 11;9:5.
Evans JM , Doki T, Fischer-Lougheed J, Davicioni E and Kearns-Jonker M, WTC06: Expression Changes in Tolerant Cardiac Allografts after Gene Therapy with a Lentiviral Vector Expressing ?1,3 Galactosyltransferase, Transplantation Proceedings, 38:3172-3180, 2006.
Evans J and Cohen G, Catecholamine Uptake Inhibitors Elevate 6-Hydroxydopamine in Brain After Administration of 6-hydroxydopa. Eur J Pharmacol, 232:241-245, 1993.
Cohen G and Evans J, Vesicular Binding of 6-Hydroxydopamine Does Not Explain the Resistance of Dopamine Nerve Terminals to 6-Hydroxydopa. Neurodegeneration, 1:241-246, 1992.
Evans JM and Cohen G, Can Trace Amounts of Neurotoxins Destroy Dopamine Neurons? Neurochemistry International, 15:127-129, 1989.
Evans JM and Cohen G, Studies on the Formation of 6-Hydroxydopamine in Brain After the Administration of 2,4,5-Trihydroxyphenylalanine (6-HydroxyDOPA). J. Neurochem, 52:1461-1467, 1989.